Author’s reply to StratonBMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e2284 (Published 27 March 2012) Cite this as: BMJ 2012;344:e2284
- Gerald Gartlehner, clinical epidemiologist1
- 1RTI-UNC Evidence-based Practice Center (USA), Austrian Cochrane Branch, 3500 Krems, Austria
Straton raises an interesting point, but his conclusion loses sight of an important factor in any statistical analysis—uncertainty.1 2 All fluvoxamine comparisons (in our 2008 and 2011 reviews) are encompassed by substantial uncertainty, as shown by …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial